-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $20

Benzinga·12/10/2025 15:59:57
Listen to the news
JP Morgan analyst Rohin Patel maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $18 to $20.